Adults and children: One or two drops in each eye four times a day at regular intervals.
Patients should be advised that the effect of ALOMIDE therapy is dependent upon its administration at regular intervals, as directed.
Improvements in signs and symptoms in response to ALOMIDE therapy (decreased discomfort, itching, foreign body sensation, photophobia, acute ocular pain, tearing, discharge, erythema/swelling, conjunctival redness, limbal reaction, epithelial disease, ptosis) are usually evident within a few days, but longer treatment for up to four weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement.
Patients should also be advised that instillation of eye drops in allergic conjunctivitis may cause discomfort initially and that this will decline with improvement of the disease (see 4.8 Undesirable Effects).
Nasolacrimal occlusion or gently closing the eyelid after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic adverse reactions.
Children less than 4 years: The safety and effectiveness of ALOMIDE in children below the age of four years have not been established.
Elderly: There are no special precautions to be followed in prescribing ALOMIDE for the elderly.
If required, corticosteroids may be used concomitantly with ALOMIDE.